<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; erosion</title>
	<atom:link href="http://www.tapanray.in/tag/erosion/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Protect Generic Drug Margin Moving Up The Value Chain</title>
		<link>http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=protect-generic-drug-margin-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 03 Dec 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[180-day]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[commoditization]]></category>
		<category><![CDATA[commodity]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[formulation]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9276</guid>
		<description><![CDATA[As an innovative drug molecule goes off-patent, it paves the way for market-entry of cheaper generic equivalents of the same. It benefits not just the patients, but all generic drug players awaiting this opportunity. But, in case of even those &#8230; <a href="http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/protect-generic-drug-margin-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Credibility Erosion of Pharma Accelerating?</title>
		<link>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-credibility-erosion-of-pharma-accelerating</link>
		<comments>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/#comments</comments>
		<pubDate>Mon, 10 Mar 2014 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerating]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[credibility]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USV]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5060</guid>
		<description><![CDATA[‘Big Pharma’ now seems to be desperately trying to gain the long lost high moral ground by pushing  hard its gigantic image makeover juggernaut, maintaining a strong pitch on the relevance of stringent Intellectual Property Rights (IPR) in the lives &#8230; <a href="http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
